Company code: Jenkem Technology Co.Ltd(688356) company abbreviation: Jenkem Technology Co.Ltd(688356) Jenkem Technology Co.Ltd(688356)
Summary of annual report 2021
Section I important tips
1 the summary of this annual report comes from the full text of the annual report. In order to fully understand the company’s operating results, financial status and future development plan, investors should http://www.sse.com.cn. The website carefully reads the full text of the annual report. 2 major risk tips the company has described in detail various risks and countermeasures that the company may face in the process of operation in this report. Please refer to section III “management discussion and analysis” of this report. 3 the board of directors, the board of supervisors and the directors, supervisors and senior managers of the company guarantee the authenticity, accuracy and completeness of the contents of the annual report, and there are no false records, misleading statements or major omissions, and bear individual and joint legal liabilities. 4. All directors of the company attended the board meeting. 5 PricewaterhouseCoopers Zhongtian Certified Public Accountants (special general partnership) issued a standard unqualified audit report for the company. 6. The company is not profitable and has not yet achieved profitability when it is listed □ yes √ No 7. The profit distribution plan or the plan for the conversion of provident fund into share capital in the reporting period adopted by the resolution of the board of directors
The company’s profit distribution plan for 2021 is as follows: the company plans to distribute cash dividends of 8.79 yuan (including tax) to all shareholders for every 10 shares based on the total share capital on the date of equity registration of dividend distribution in 2021, and the total amount of cash dividends is expected to be 5274000000 yuan, accounting for 30% of the net profit attributable to shareholders of Listed Companies in the consolidated statements of the company in 2021; The company does not convert the capital reserve into share capital and does not give bonus shares. The amount of cash dividends in the above profit distribution plan for 2021 is temporarily calculated based on the current total share capital of the company of Shanghai Pudong Development Bank Co.Ltd(600000) 00 shares, and the total amount of cash dividends actually distributed will be calculated based on the total share capital on the registration date of dividends and dividends in 2021. The company’s 2021 profit distribution plan has been deliberated and approved at the 17th meeting of the second board of directors of the company, and needs to be deliberated and approved by the 2021 annual general meeting of shareholders of the company. 8. Whether there are important matters such as special arrangements for corporate governance □ applicable √ not applicable
Section II basic information of the company
1 company profile company stock profile √ applicable □ not applicable
Company stock profile
Stock type stock exchange stock abbreviation before stock code change stock abbreviation and sector
RMB common stock Shanghai Stock Exchange Jenkem Technology Co.Ltd(688356) Jenkem Technology Co.Ltd(688356)
Scientific innovation board
Profile of the company’s depositary receipts □ applicable √ not applicable contact person and contact information
Contact person and contact information secretary of the board of directors (domestic representative of information disclosure) securities affairs representative
Name: Chen Bin, Chang Yiqun
Office address: No. 66, xixiaokou Road, Haidian District, Beijing Beijing Centergate Technologies (Holding) Co.Ltd(000931) No. Jenkem Technology Co.Ltd(688356) No. Beijing Centergate Technologies (Holding) Co.Ltd(000931) No. 66sheng Science Park, xixiaokou Road, Haidian District, Beijing Jenkem Technology Co.Ltd(688356)
Tel: 010828937 Gansu Yasheng Industrial (Group) Co.Ltd(600108) 2893760
E-mail [email protected]. [email protected].
2. Introduction to the company’s main business in the reporting period (I) main business, main products or services
Jenkem Technology Co.Ltd(688356) mainly engaged in the R & D, production and sales of medical polyethylene glycol and its active derivatives. At the same time, based on its polyethylene glycol synthesis and PEGylation technology with independent intellectual property rights, it provides innovative technical services for polyethylene glycol pharmaceutical application to downstream customers, and independently develops innovative polyethylene glycol drugs and class III medical devices. During the reporting period, Jenkem Technology Co.Ltd(688356) operating income mainly came from the sales of polyethylene glycol materials and related technical services. The above self-developed polyethylene glycol modified drugs and class III medical devices are still in the stage of preclinical research or phase II clinical research, and have not obtained income Jenkem Technology Co.Ltd(688356) is in a leading position in China in the research and development, production and pharmaceutical application of polyethylene glycol and its active derivatives. It is one of the few companies outside China that can carry out the industrial production of medical polyethylene glycol and its active derivatives with high purity and low dispersion, filling the gap of large-scale production of high-quality medical polyethylene glycol and its derivatives in China for a long time, It is a major emerging player in the global market.
Jenkem Technology Co.Ltd(688356) ‘s main products are medical polyethylene glycol derivatives with high purity and low dispersion. At the same time, based on its polyethylene glycol synthesis and PEGylation technology with independent intellectual property rights, it provides innovative technical services for polyethylene glycol pharmaceutical application to downstream customers, and independently develops innovative polyethylene glycol drugs and class III medical devices. As a R & D and production enterprise of new materials, the company’s main revenue still comes from medical polyethylene glycol and its derivatives.
(1) Main products
The company’s main products are medical polyethylene glycol and its active derivatives. At present, there are more than 600 commonly used subdivision products in the product catalogue, and customized development and industrial production can be provided according to the special application needs of customers. The chemical structure of polyethylene glycol (PEG) is ho – (CH2CH2O) N-OH, which is the general name of ethylene glycol polymers with relative molecular weight of 200 ~ 8000 and above. Polyethylene glycol is the best biocompatible synthetic material in known polymers. It has the advantages of low toxicity, low immunogenicity and excellent biocompatibility. It is often used to combine with various drugs or prepare medical devices in the pharmaceutical industry. Starting from polyethylene glycol, polyethylene glycol derivatives can be prepared by accurately introducing functional groups with strong reaction activity at its specific molecular end through chemical synthesis reaction.
Due to the introduction of a variety of groups, polyethylene glycol derivatives have greatly expanded their original application scope on the basis of inheriting various excellent properties of polyethylene glycol. For example, they can be combined with various drug molecules, which can not only maintain the efficacy, but also bring the advantages of slowing down the attenuation of drugs and reducing toxicity. According to the different molecular weight, spatial conformation and end groups of polyethylene glycol derivatives, they can be divided into single molecular weight polyethylene glycol derivatives, methoxy polyethylene glycol derivatives, Y-branched polyethylene glycol derivatives and multi arm polyethylene glycol derivatives.
(2) Main technical services
Jenkem Technology Co.Ltd(688356) with a deep understanding of the synthesis and application of polyethylene glycol and its active derivatives, it has formed a series of patented and non patented technologies. Based on this, it provides innovative technology services for polyethylene glycol pharmaceutical application to downstream customers and obtains technical service income. That is, after the issuer obtains relevant patents, clinical trial approvals and other intellectual property rights through independent research and development, it will authorize or transfer them to downstream customers. The downstream customers will complete process development, clinical research, new drug registration and large-scale production with the technical support of the company, and pay the patent licensing fee, milestone income, income share, etc. to the issuer.
In addition, relying on the rich experience accumulated in the synthesis and application of polyethylene glycol and its active derivatives, the company actively extends to the downstream application field and independently researches and develops polyethylene glycol modified drugs and class III medical devices. At present, the issuer has developed several products under development in the fields of tumor treatment, local pain relief, biological immunosuppression and medical beauty, such as polyethylene glycol irinotecan, jk-1221h, jk-1119i, etc. The above independently developed polyethylene glycol modified drugs and class III medical devices are still in the stage of preclinical research or phase I clinical research. Among them, only one drug polyethylene glycol irinotecan has entered the phase II clinical trial, and no income has been obtained during the reporting period Jenkem Technology Co.Ltd(688356) although engaged in the research and development of polyethylene glycol modified drugs and class III medical devices, the company does not intend to complete all the research and development of the above drugs or devices and market them in the future. Instead, it is expected to seek external transfer or authorization when the research and development work has made certain progress, so as to further tap the commercial value of polyethylene glycol materials and polyethylene glycol technology. （2） Main business modes (1) procurement mode
According to the production and quality control requirements, the company inspects and evaluates the business qualification, quality system, supply stability, after-sales service and price of suppliers, and prepares the list of qualified suppliers to ensure that the supplied materials can meet the specified requirements of the company’s quality system. For the purchase of production materials, according to the supplier quality audit management procedure, purchase contract management procedure and other relevant system documents, the relevant user departments shall put forward the purchase plan for the next month according to the demand and budget in the current month, and submit it to the general management department for purchase after being reviewed by the department head. After the arrival of purchased products, the quality department shall inspect them first, the warehouse personnel shall count and receive them into the warehouse, and then the financial department shall be responsible for settlement.
(2) Production mode
Jenkem Technology Co.Ltd(688356) the production mainly includes the production of medical polyethylene glycol raw materials and medical polyethylene glycol derivatives. Liaoning Jiankai is responsible for the production of medical polyethylene glycol raw materials and provides it to Tianjin Jiankai to produce medical polyethylene glycol derivatives. For standardized products, the production department arranges production according to the sales plan and ensures a certain product reserve; For customized products, the company’s synthesis research department and production department develop synthesis routes according to customer needs and product characteristics, and organize large-scale production after successful trial production. The quality department of the company participates in the whole production process: the quality assurance department (QA) is mainly responsible for the operation, supervision, compliance confirmation and improvement of quality system management; The quality control department (QC) is responsible for the inspection and release of production materials, products in process and finished products. The company’s quality assurance department and quality control department work together to ensure that the production process is implemented as planned and that the product quality meets the requirements of external sales. The company has formulated a complete set of production related management systems and specifications, and obtained ISO9001 quality management system certification, ISO13485 medical device quality management system certification and other quality system certification at home and abroad.
(3) Sales model
Jenkem Technology Co.Ltd(688356) adopts the direct selling mode to carry out sales at home and abroad. Customers include well-known pharmaceutical enterprises and major scientific research institutions at home and abroad. Since its establishment, Jenkem Technology Co.Ltd(688356) actively explored overseas customers, and cut into customer business by providing services such as polyethylene glycol molecular structure design, production process verification, determination of analytical methods, pharmacological and toxicological evaluation to overseas medical device or drug manufacturer customers in the early R & D stage, and finally realized product sales revenue by selling its designated polyethylene glycol derivatives to customers. Due to the popularity of the company in the industry, downstream customers such as scientific research institutions, pharmaceutical enterprises and medical device enterprises will take the initiative to contact the company to obtain the latest product catalogue and place orders when they have the purchase demand for medical polyethylene glycol active derivatives; If there is no required product in the product catalog or there is personalized product demand, the company can provide customers with highly customized polyethylene glycol active derivatives based on R & D capability. In addition, the company also improves the company’s popularity by participating in exhibitions and other ways, actively understands the needs of potential customers, and carries out targeted promotion of enterprises and their products.
Before selling polyethylene glycol derivatives, Jenkem Technology Co.Ltd(688356) can provide customized development services for customers, including: ① molecular structure design: design the structure of polyethylene glycol derivatives, develop synthetic routes and processes, and formulate quality standards according to customers’ specific medical functional requirements; ② Synthetic route development: according to the specific structural requirements of polyethylene glycol derivatives, develop synthetic routes and processes, and formulate quality standards.
In principle, the company does not charge fees for the above-mentioned early screening and customized development business, but obtains sales revenue through subsequent product sales. Due to the difficulty and scarcity of customized development provided by the company, it can not only exchange for higher sales gross profit margin or customer purchase commitment and other rights and obtain greater benefits, but also meet the needs of expanding main business and protecting core technology Jenkem Technology Co.Ltd(688356) in the future, the existing sales model will continue to be the main sales model. （3） Industry 1 Development stage, basic characteristics and main technical threshold of the industry
Jenkem Technology Co.Ltd(688356) produced and sold medical polyethylene glycol and its polyethylene glycol derivatives belong to fine chemicals. According to the industrial classification of national economy (GB / t47542017) and the industrial classification guidelines for listed companies (revised in 2012) of China Securities Regulatory Commission, the industry of the company is “C26 chemical raw materials and chemical products manufacturing industry”. Enterprises in the fine chemical industry operate independently facing the market, and their industry supervision system is the market regulation and management system under the national macro guidance. Government functional departments carry out industrial macro-control, and industry associations carry out self-discipline and standardization. The application fields of medical polyethylene glycol and its derivatives of the issuer are pharmaceutical industry and medical device manufacturing industry, which has high requirements for product quality. Therefore, in addition to the standard requirements of laws and regulations, the issuer actively refers to the relevant standards of the pharmaceutical industry for management to ensure that the product quality meets the production requirements of customers.
Polyethylene glycol is the polymer with the lowest level of absorption by proteins and cells. At room temperature, polyethylene glycol is easily soluble in water, ethanol and most common solvents, and is non-toxic, harmless and non irritating to human body. It has good biocompatibility, lubricity and moisturizing. Polyethylene glycol is widely used in various industries and can be seen everywhere in daily life.
Although polyethylene glycol is widely used, it is very difficult to produce high-purity polyethylene glycol raw materials for the pharmaceutical industry. Medical pharmaceutical polyethylene glycol derivatives are important materials in the production and preparation of downstream raw materials and polyethylene glycol gel medical devices. In addition to their high molecular weight, they have high standards for purity, polydispersity and impurity content. In 2020, the National Pharmacopoeia Committee issued the “general theory of pegylated recombinant protein and polypeptide products for human use”, which made clear requirements for polyethylene glycol: “appropriate polyethylene glycol should be selected for modification, and the quality attributes such as the type of active group, the bond type of bond, molecular morphology and molecular weight range should be defined to
